(IN BRIEF) EQT Life Sciences announces the acquisition of its portfolio company, Amolyt Pharma, by Alexion, AstraZeneca Rare Diseases, for a total deal value of $1.05 billion. This acquisition underscores Amolyt’s significant advancements in developing novel treatments for rare endocrine … Read the full press release
Posted in Business, Environment, European Union, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, Alexion, Amolyt Pharma, AstraZeneca Rare Diseases, Eneboparatide, EQT Life Sciences, Felice Verduyn-van Weegen, Healthcare, hypoparathyroidism, partnership, sustainability, Thierry Abribat
(IN BRIEF) Soliris (eculizumab) has received approval in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). This makes Soliris the first and only complement inhibitor approved for NMOSD … Read the full press release
(IN BRIEF) Alexion, a subsidiary of AstraZeneca Rare Disease, is set to present new data at the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, Alize Vives, Anna Francis, AQP4, AstraZeneca, Christophe Hotermans, ECTRIMS-ACTRIMS Meeting, effectiveness, Jin Nakahara, Justin Lee, Michael Levy, multiple sclerosis, NMOSD, Rare Neurological Disorder, rituximab, Sami Fam, Soliris, treatment, Ultomiris, Viktoria Papp
(IN BRIEF) Alexion, in collaboration with AstraZeneca Rare Disease, has finalized an agreement to acquire a collection of preclinical rare disease gene therapy programs and related technologies from Pfizer Inc. This strategic move combines the expertise of Alexion and AstraZeneca … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged acquisition, Adrian Kemp, Alexion, AstraZeneca, AstraZeneca Rare Disease, gene therapy, genomic medicine, partnership, Pfizer
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition (PRESS RELEASE) CAMBRIDGE, 7-Jan-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, amyloid fibril deposits, amyloidosis, AstraZeneca, ATTR-CM, cardiomyopathies, Heart, heart failure, human monoclonal antibody, licence agreement, Marc Dunoyer, misfolded transthyretin, Neurimmune AG, NI006, rare disease, transthyretin amyloid cardiomyopathy
(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its rare diseases arm Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences, Inc., a Clinical Stage … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abnormal antibody, acquisition, AL amyloidosis, Alexion, amyloids, AstraZeneca, bone marrow, CAEL-101, Caelum Biosciences, Cardiac Amyloid Reaching for Extended Survival, CARES Phase III clinical programme, defective plasma cells, IIIb disease, immunoglobulin, light chain (AL) amyloidosis, mAb, Marc Dunoyer, Mayo stage IIIa, monoclonal antibody, rare disease
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
